A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Journal of Clinical Apheresis · 2025
DOI: 10.1002/jca.70017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Apheresis, 2025. Verfasst von Jeremy W Jacobs und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Blood Component Removal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Immune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time‐period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty‐day mortality was 3.7% (14/374), and 6‐month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Pathology, University of California San Diego, La Jolla, California, USA.
- Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Jeremy W Jacobs, Brian D Adkins, Garrett S Booth, Caroline G Stanek, Brenda J Grossman, Laura D Stephens, Elizabeth P Crowe, Marisa B Marques, Chisa Yamada, Justin E Juskewitch, Ingrid Perez-Alvarez, Meredith G Parsons, Annette J Schlueter, Christopher A Tormey, Sean G Yates, Evan M Bloch, Jay S Raval
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
- National Heart, Lung, and Blood Institute
Zitieren
APA
Jacobs, J. W., Adkins, B. D., Booth, G. S., Stanek, C. G., Allen, E. S., Grossman, B. J., Stephens, L. D., Crowe, E. P., Daou, L., Marques, M. B., Siniard, R. C., Wallace, L. R., Yamada, C., Duque, M. A., Wu, Y., Aljuboori, O., Harrington, T. J., Byrnes, D. M., Eichbaum, Q., …, & Raval, J. S. (2025). A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70017
Vancouver
Jacobs JW, Adkins BD, Booth GS, Stanek CG, Allen ES, Grossman BJ, et al. A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70017
BibTeX
@article{Jacobs2025,
author = {Jacobs, Jeremy W and Adkins, Brian D and Booth, Garrett S and Stanek, Caroline G and Allen, Elizabeth S and Grossman, Brenda J and Stephens, Laura D and Crowe, Elizabeth P and Daou, Laetitia and Marques, Marisa B and Siniard, Rance C and Wallace, Lisa R and Yamada, Chisa and Duque, Miriam Andrea and Wu, Yanyun and Aljuboori, Omar and Harrington, Thomas J and Byrnes, Diana M and Eichbaum, Quentin and Figueroa Villalba, Cristina A and Juskewitch, Justin E and Klapper, Ellen and Perez-Alvarez, Ingrid and Klein, Monica S and Aldarweesh, Fatima and Alkhateb, Rahaf and Parsons, Meredith G and Schlueter, Annette J and Tormey, Christopher A and Wheeler, Allison P and Powers, Amy A and Webb, Christopher B and Yates, Sean G and Bloch, Evan M and Raval, Jay S},
title = {A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021},
journal = {Journal of Clinical Apheresis},
year = {2025},
doi = {10.1002/jca.70017}
}
EUVIMED